Purchase Short-Term Access
Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes
Lorraine L. Lipscombe, MD, MSc
Annals of Internal Medicine 2009;151:JC4-8.
doi:10.7326/0003-4819-151-8-200910200-02008
Purchase Online access to this article for 24 hours
